Connect with us

Headlines

Allergan Will Say No Thanks to $46 Billion Take-Over Bid

mm

Published

on

The company says Valeant would cut back on research.

Reports say that Botox-maker Allergan this week will reject the $46 billion take-over offer from rival Valeant Pharmaceuticals, which recently acquired Bausch & Lomb, setting the stage for what the Financial Times calls “a hostile takeover battle at the top of the US drugmaking industry.” Allergan is expected to raise concerns that Valeant would cut research and development as a reason for refusing the offer. The acquisition would create the pre-eminent global powerhouse in the eyecare industry.

Read more at Financial Times |
Toronto Star

SPONSORED VIDEO

Turn Patients Into Loyal Eyewear Shoppers

80% of patients are browsing eyewear online, are you influencing patients online before your competition? Join thousands of practices thriving with Optify, voted the #1 optical sales tool by EyeVote. Empower your opticians to save time, increase optical revenue, and maximize your EHR data and website with a seamless optical plug-in that keeps patients buying from YOU! Now through August 31st receive a $25 UberEats® gift card when you complete a 15 min demo. Book your demo here..

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular

Link partner: indobet autowin88 vegasslot77 mantra88 ligasedayu warungtoto login sbobet vegas4d indobet ingatbola88 ligaplay dewagg hoki368 qqnusa ligagg zeus138 bro138 bos88 ligaciputra